Lipitor Clone Gets Ranbaxy Laboratories (RANBAXY.BO) $600 Million  
8/10/2012 7:04:24 AM

For the Gurgaon-based Ranbaxy Laboratories, the generic version of the world’s top-selling drug, the anti-cholesterol Lipitor (global sales: about $13 billion), has proved a whopping money-spinner during its exclusivity period of six months to May 29. Over $600 million has been raked in, a testimony to Ranbaxy’s successful monetisation of the exclusivity opportunity. Ranbaxy’s CEO and MD Arun Sawhney told analysts in a conference call that the company enjoyed a 55% market share during the exclusivity period. “In the post-exclusivity period, we still have a share of about 40%.”